JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Expression of m6A-related factors in pulmonary sarcomatoid carcinoma

  • 0Department of Pathology, The Second Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, China; Department of Nutrition, Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, China.
Pathology, Research and Practice +

|

July 12, 2025

|

July 12, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

Pulmonary sarcomatoid carcinoma (PSC) is a rare lung cancer. This study found downregulated m6A factors during its sarcomatoid transformation, suggesting a role for epithelial-mesenchymal transition (EMT) and offering potential diagnostic targets.

Area Of Science

  • Oncology
  • Molecular Biology
  • Pathology

Background

  • Pulmonary sarcomatoid carcinoma (PSC) is an aggressive subtype of non-small cell lung carcinoma (NSCLC).
  • PSC is characterized by epithelial-mesenchymal transition (EMT), leading to sarcomatoid transformation.
  • Understanding the molecular mechanisms, including epigenetic modifications like m6A, is crucial for PSC diagnosis and treatment.

Purpose Of The Study

  • To investigate the expression levels of m6A-related factors in pulmonary sarcomatoid carcinoma.
  • To analyze the clinicopathological features of PSC patients.
  • To explore the role of m6A dysregulation in EMT during lung cancer sarcomatoid transformation.

Main Methods

  • Retrospective analysis of ten PSC patients diagnosed between 2018 and 2022.
  • Clinical and pathological data collection, including symptoms, imaging, and histomorphology.
  • Immunohistochemistry to assess cytokeratin, Vimentin, and various m6A-related factors (Writers, Erasers, Readers) in carcinomatoid and sarcomatoid components.

Main Results

  • PSC predominantly affects middle-aged to elderly male smokers, with tumors often located in the right upper lobe.
  • Immunohistochemistry showed downregulated cytokeratin and upregulated Vimentin in sarcomatoid areas, confirming EMT.
  • Significant downregulation of several m6A Writers (METTL3, METTL16, WTAP), Erasers (FTO, ALKBH5), and Readers (YTHDC1, YTHDC2, YTHDF1) was observed in sarcomatoid versus carcinomatoid components.

Conclusions

  • Pulmonary sarcomatoid carcinoma exhibits distinct clinicopathological features and aggressive progression.
  • m6A RNA methylation pathway is dysregulated during the sarcomatoid transformation of lung cancer, likely involving EMT.
  • Aberrant expression of m6A factors presents potential diagnostic biomarkers and therapeutic targets for PSC.

Keywords:

Related Concept Videos

Abnormal Proliferation 02:23

4.6K

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

mTOR Signaling and Cancer Progression 03:03

3.9K

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Mitogens and the Cell Cycle 02:38

6.9K

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...